市场调查报告书
商品编码
1154880
宏基因组学全球市场规模、份额、行业趋势分析报告按工作流程、按产品(试剂盒/试剂、测序/数据分析服务、软件)、技术、应用、地区、展望和预测2022-2028Global Metagenomics Market Size, Share & Industry Trends Analysis Report By Workflow, By Product (Kits & Reagents, Sequencing & Data Analytics Services and Software), By Technology, By Application, By Regional Outlook and Forecast, 2022 - 2028 |
到 2028 年,全球宏基因组学市场规模预计将达到 32 亿美元,预测期内復合年增长率为 13.6%。
最近的研究使用“鸟枪法”或 PCR 定向测序从样本群落的所有成员中获取几乎无偏差的所有基因样本。宏基因组学一词源于这样一种观念,即可以像研究单个基因组一样研究一组已排序的环境基因。作为 DNA 的来源,常规测序从相同细胞的培养开始。然而,早期的宏基因组学研究表明,在某些栖息地,无法培养广泛的微生物群落,因此无法对其进行测序。
因此,发现了多个与已知养殖物种不对应的 16S rRNA 序列,揭示了许多非分离生物的存在。这些对直接从环境中提取的核醣体 RNA 基因的研究表明,基于培养的方法可以检测到样品中不到 1% 的细菌和古细菌。大量以前未被认识的微生物的发现极大地促进了宏基因组学分析的传播。
COVID-19 影响分析
自 COVID-19 出现以来,生命科学和生物技术行业的主要参与者都在寻求跟踪、诊断和治疗 COVID-19 的解决方案。宏基因组学分析对于病毒发现和跟踪至关重要。已经引入了多种序列监测解决方案和平台以进行有效的感染诊断。例如,2021 年 5 月,牛津大学与 Oracle 建立了战略合作关係,以开发强大的基于云的基因组测序和分析平台,以降低冠状病毒感染的风险。由于对 COVID-19 药物和疫苗发现的特殊需求,宏基因组学市场的经济活动正在加速。
市场增长因素
NGS平台的技术不断进步
测序技术的持续进步促成了高效、便携且用户友好的 NGS 平台的开发,这些平台可以提供快速准确的结果并缩短周转时间。此类产品和技术的推出让玩家获得了立竿见影的竞争优势,因此主要玩家都在加大研发投入,以提高市场地位和份额。由于技术改进,许多新的生物信息学工具被添加到宏基因组学市场,增加了市场收入。
大数据NGS数据分析
全基因组测序过程中生成的数据量通常为 TB 级。数据管理是基于 NGS 的宏基因组测序的最终用户面临的主要挑战。由于数据格式的差异以及不同 NGS 平台的数据输出缺乏行业标准,数据保留要求可能非常复杂。通过将大数据技术和人工智能应用于NGS分析和工作流程管理,NGS运行的良率得到显着提高。随着测序技术的发展,测序过程中收集的数据量也在不断增加。
市场约束
发展中国家的最终用户预算限制
在发展中国家,大部分学术研究和开发都依赖于其他资金。即使 NGS 测序仪的成本下降,它们仍然非常昂贵。 NovaSeq 5000 和 6000 是 Illumina 最强大的测序仪,在美国的售价在数百到数万美元之间。
产品概览
宏基因组学市场按产品细分为试剂盒和试剂、测序和数据分析服务以及软件。试剂盒和试剂部分在 2021 年的宏基因组市场中占据了最高的收入份额。这是因为在测序的实验样品製备阶段使用了不同的化学品。 F. Hoffmann-La Roche Ltd、Thermo Fisher Scientific 和 Illumina Inc. 等知名公司提供多种试剂以满足您的测序需求。
技术展望
宏基因组学市场按技术细分为鸟枪法测序、16S 测序、全基因组测序等。 2021 年,全基因组测序部分在宏基因组学市场中占据了相当大的收入份额。全基因组测序,也称为全基因组测序,是一种一次性确定生物体基因组的所有或几乎所有 DNA 序列的方法。
工作流程概览
宏基因组学市场按工作流程细分为预测序、测序和数据分析。 2021 年,预测序部分在宏基因组学市场中占据了重要的收入份额。预测序注意事项包括文库大小、读取持续时间和类型(单端或双端)以及测序深度的选择。测序后决策包括预处理步骤、参考库和映射技术的选择。
应用展望
根据在环境、临床诊断、药物发现、生物技术、食品和营养等领域的应用,宏基因组学市场分为两部分。到 2021 年,环境部门将在宏基因组学市场中占据最大的收入份额。宏基因组学在农业和环境保护方面的研究领域正在迅速扩大。宏基因组学是一种通过序列分析和基因筛选了解特定环境微生物的新方法。
区域展望
按地区划分,在北美、欧洲、亚太地区和 LAMEA 进行了分析。到 2021 年,北美部分将在宏基因组学市场中占据最大的收入份额。这种优势可能是由于研发资金的增加和测序技术的进步,该地区出现了大公司。公司与学术机构之间的合作是该地区最重要的商业战略之一。
The Global Metagenomics Market size is expected to reach $3.2 billion by 2028, rising at a market growth of 13.6% CAGR during the forecast period.
The study of genetic material extracted directly from samples collected is known as metagenomics. This expansive field is also known as environmental genomics, ecogenomics, and community genomics. While conventional microbiology, microbial genome sequencing, and genomics rely on produced clonal cultures, the early environmental genetic analysis relied on cloning certain genes (typically the 16S rRNA gene) to generate a profile of variety in a wild sample.
It demonstrated that cultivation-based approaches have missed the large bulk of microbial biodiversity. Metagenomics has the potential to transform knowledge of the whole living universe as a result of its ability to uncover the hitherto hidden diversity of microorganisms. As the cost of DNA sequencing continues to decline, metagenomics now enables the investigation of microbial ecology on a much larger scale and in greater depth than ever before.
Recent studies use "shotgun" or PCR-directed sequencing to obtain largely unbiased samples of all genes from all sampled community members. The term metagenome referred to the concept that a collection of sequenced environmental genes might be studied similarly to a single genome. As a source of DNA, conventional sequencing begins with a culture of identical cells. However, early metagenomic investigations indicated that broad groups of microbes in several habitats could not be cultivated and hence cannot be sequenced.
Multiple 16S rRNA sequences that do not correspond to any known cultured species have been discovered, indicating the existence of numerous non-isolated organisms. These surveys of ribosomal RNA genes extracted directly from the environment demonstrated that cultivation-based approaches detect less than one percent of the bacterial and archaeal organisms in a sample. The discovery that the great majority of microorganisms were previously unrecognized is largely responsible for the growing popularity of metagenomics.
COVID-19 Impact Analysis
Since the emergence of COVID-19, important players in the life sciences and biotechnology industries have sought solutions for COVID-19 tracking, diagnosis, and treatment. The analysis of metagenomics is vital for the discovery and tracking of the virus. Diverse sequencing monitoring solutions and platforms are being implemented for efficient infection diagnosis. In May 2021, for instance, Oxford University and Oracle established strategic cooperation to develop a robust cloud-based genomic sequencing and analysis platform to reduce the risk of coronavirus infection. Due to the exceptional demand for COVID-19 medication and vaccine discovery, economic activity in the metagenomics market is accelerating.
Market Growth Factors
Constant Technological Advancements In NGS Platforms
Continuous technological advancements in sequencing techniques have enabled the development of efficient, portable, and user-friendly NGS platforms that are capable of delivering speedy and accurate results and have a reduced turnaround time. The introduction of such products and technology offers players an immediate competitive advantage; hence, leading companies are investing more in R&D to increase their market positions and shares. Many new bioinformatics tools have been added to the metagenomics market as a result of technical improvements, which have increased the market's revenue.
NGS Data Analysis With Big Data
The amount of data generated during whole-genome sequencing is often at the terabyte level. For end-users of NGS-based metagenomic sequencing, data management is a significant challenge. Due to differences in data formats and the lack of an industry-wide standard for data output from different NGS platforms, data storage requirements can be rather complex. The application of big data technologies and AI for NGS analysis and workflow management has considerably boosted the yield of NGS runs. With developments in sequencing technology, the quantity of data collected during a sequencing run likewise grows.
Market Restraining Factors
Constrained End-User Budgets In Developing Nations
Academic research and development are almost entirely reliant on financial support from other sources in nations that are still considered to be developing. NGS sequencers continue to be prohibitively costly even though the cost of NGS sequencing has come down. The NovaSeq 5000 and 6000 are Illumina's two most sophisticated sequencing systems, and their prices range from hundreds to tens of thousands of US dollars.
Product Outlook
Based on the Product, the Metagenomics Market is segmented into Kits & Reagents, Sequencing & Data Analytics Services, and Software. The kits & reagents segment acquired the highest revenue share in the metagenomics market in 2021. It is because, during the experimental sample preparation phase of sequencing, a variety of chemicals are utilized. Established firms such as F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific, and Illumina Inc. offer an extensive selection of reagents to meet the needs of sequencing.
Technology Outlook
On the basis of Technology, the Metagenomics Market is divided into Shotgun Sequencing, 16S Sequencing, Whole Genome Sequencing, and Others. The whole genome sequencing segment recorded a substantial revenue share in the metagenomics market in 2021. Whole genome sequencing, also known as whole genome sequencing, complete genome sequencing, and entire genome sequencing, is the method of determining all or almost all of the DNA sequences of an organism's genome at once.
Workflow Outlook
By Workflow, the Metagenomics Market is classified into Pre-sequencing, Sequencing, and Data Analysis. The pre-sequencing segment registered a significant revenue share in the metagenomics market in 2021. Pre-sequencing considerations include a selection of library size, read duration and type (single or paired-end), and sequencing depth. Post-sequencing decisions consist of choosing pre-processing stages, a reference library, and a mapping technique.
Application Outlook
Based on the Application, the Metagenomics Market is bifurcated into Environmental, Clinical Diagnostics, Drug Discovery, Biotechnology, Food & Nutrition, and Others. The environmental segment acquired the largest revenue share in the metagenomics market in 2021. The space for metagenomics research in agriculture and environmental protection is expanding fast. Metagenomics is a novel approach to comprehending microorganisms from a certain environment by sequencing analysis or gene screening.
Regional Outlook
Region-wise, the Metagenomics Market is analyzed across North America, Europe, Asia Pacific, and LAMEA. The North America segment garnered the largest revenue share in the metagenomics market in 2021. This dominance can be attributed to the presence of major corporations in the region with increasing R&D funding and technological advances in sequencing. Collaboration between businesses and academic institutions is one of the region's most important business strategies.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Rad Laboratories, Inc., Illumina, Inc., PerkinElmer, Inc., Thermo Fisher Scientific, Inc., Novogene Co., Ltd., Promega Corporation, Qiagen N.V., Takara Bio, Inc. (Takara Holdings Inc.), Oxford Expression Technologies Ltd., and F. Hoffmann-La Roche Ltd.
Strategies deployed in Metagenomics Market
Jun-2022: Oxford Nanopore unveiled a novel protocol for the rapid metagenomic characterization of DNA and RNA viruses. The protocol represents a simple metagenomic workflow that can be utilized to recognize DNA and RNA viruses. Moreover, this method has been applied in human clinical specimens to describe the pathogen presently known as the monkeypox virus.
Jun-2022: Illumina completed the acquisition of IDbyDNA, a company producing metagenomic technology. Under this acquisition, IDbyDNA delivers a respiratory pathogen panel enrichment kit that recognizes more than 280 pathogens, including SARS-CoV-2, and more than 1,200 antimicrobial resistance alleles. Moreover, it operates on Illumina's NextSeq 550 sequencing system and employs IDbyDNA's Explify analysis software.
Mar-2022: QIAGEN signed a two-year agreement with National Health Service, a publicly funded healthcare system in England. Through this agreement, Human Gene Mutation Database would be utilized at seven sites to help understand genomic data from next-generation sequencing. Additionally, NGS data from over 2.5 million clinical cases are now researched and diagnosed by QIAGEN Digital Insights solutions
Nov-2021: Novogene introduced single-cell sequencing services. The service offers an on-site service for Novogene Japan K.K. to support consumers in optimizing their single-cell preparation work. Moreover, it delivers the flexibility for investigators to enjoy a reliable and hassle-free experience of an end-to-end sequencing solution for their single-cell analysis from experimental project design, library preparation, cell barcoding, bioinformatic analysis, and sequencing.
Jun-2021: Illumina came into a partnership with Microba Life Sciences, world-leading technology for measuring the human gut microbiome. Together, the companies aimed to obtain Illumina's revolutionary NGS tools and Microba's high-quality proprietary gut microbiome analysis platform to develop the precise metagenomic data that researchers need to boost findings. Moreover, Microba Life Sciences is growing human health with new solutions produced from the human gut microbiome.
Mar-2021: NovogeneAIT Genomics expanded its geographical footprint by establishing a single-cell sequencing lab in Singapore. This expansion includes a facility to deliver an entire end-to-end solution of the single-cell gene expression services such as single-cell experimental design, sequencing, data analysis, and single-cell capture. Additionally, the single-cell lab would deliver its services utilizing the 10x Illumina platforms and Genomics Chromium System.
Mar-2020: Illumina formed a partnership with IDbyDNA, a metagenomics technology enterprise. Through this partnership, the companies aimed to boost NGS adoption for clinical infectious sickness testing.
Oct-2019: Novogene expanded its geographical footprint by increasing its capacity to Cambridge Science Park. This expansion contains plant and animal genome sequencing, metagenome sequencing, human genome sequencing, transcriptome sequencing, and lanes sequencing. Moreover, the Novogene Cambridge Sequencing Centre is now able of performing more than 280,000 human WGS analyses every year.
Market Segments covered in the Report:
By Workflow
By Product
By Technology
By Application
By Geography
Companies Profiled
Unique Offerings from KBV Research
List of Figures